Print
08 November 2017
GMP News
The volume of antibiotics market in Russia reached 19.7 billion rubles in prices of final consumption or 120 million packages. Compared to the same period of 2016, this segment grew by 3.9% in monetary terms and remained virtually unchanged in physical terms. This was revealed by the retail audit of QuintilesIMS for 8 months of 2017.
The analysis of the market structure allowed to identify the differences in the consumption of Russian-made and imported medicinal products. For example, an increasing share of sales comes from antibiotics manufactured in Russia. Following 8 months of 2017, they account for 54% of the total market in physical terms, or 3.3% more than a year earlier. In the period under review, the sales of Russian-made antibiotics reached 4.4 billion rubles in retail prices or 64.5 million packages.
At the same time, there was a noticeable drop in the sales of imported antibiotics. For 8 months of 2017, they amounted 55.5 million packages, or 4.8% less than over the same period of 2016. This trend may indicate a strengthening of positions held by Russian manufacturers in the antibiotics market and successful implementation of the import substitution program.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.